Selegiline and oxidative stress in HIV-associated cognitive impairment

Neurology

Volumn 73, Issue 23, 2009, Pages 1975-1981

  Schifitto, G ^a   Yiannoutsos, C T ^b   Ernst, T ^c   Navia, B A ^d   Nath, A ^e   Sacktor, N ^e   Anderson, C ^e   Marra, C M ^f   Clifford, D B ^g  

^a UNIVERSITY OF ROCHESTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; N ACETYLASPARTIC ACID; PLACEBO; PROTEIN; SELEGILINE;

ADULT; ARTICLE; BASAL GANGLION; CLINICAL EVALUATION; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VIRUS LOAD;

EID: 73349099696     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181c51a48     Document Type: Article

References (42)

1. Jones G, Power C. Regulation of neural cell survival by HIV-1 infection. Neurobiol Dis 2006;21:1-17.
2. Turchan J, Pocernich CB, Gairola C, et al. Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants. Neurology 2003;60:307-314.
3. Sacktor N, Haughey N, Cutler R, et al. Novel markers of oxidative stress in actively progressive HIV dementia. J Neuroimmunol 2004;157:176-184.
4. Haughey NJ, Cutler RG, Tamara A, et al. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 2004;55:257-267.
5. Bandaru VV, McArthur JC, Sacktor N, et al. Associative and predictive biomarkers of dementia in HIV-1-infected patients. Neurology 2007;68:1481-1487.
6. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002;8:136-142.
7. Schifitto G, Zhang J, Evans SR, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 2007;69:1314-1321. (Pubitemid 47482445)
8. Carrillo MC, Kitani K, Kanai S, Sato Y, Miyasaka K, Ivy GO. (-)-Deprenyl increases activities of superoxide dis-mutase and catalase in certain brain regions in old male mice. Life Sci 1994;54:975-981.
9. Salo PT, Tatton WG. Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 1992;31: 394-400.
10. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991;30:666-672.
11. Matsui Y, Kumagae Y. Monoamine oxidase inhibitors prevent striatal neuronal necrosis induced by transient fore-brain ischemia. Neurosci Lett 1991;126:175-178.
12. Ansari KS, Yu PH, Kruck TP, Tatton WG. Rescue of axo-tomized immature rat facial motoneurons by R(-)-depre-nyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 1993;13:4042-4053.
13. Tatton WG, Chalmers-Redman RME. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neu-rodegeneration. Neurology 1996;47:S171-S183.
14. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Safety and tolerability of thioctic acid and deprenyl in HIV dementia. Neurology 1998;50:645-651.
15. Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, Kieburtz K. Transdermal selegiline in HIV-associated cognitive impairment: pilot placebo-controlled study. Neurology 2000;54:233-235.
16. Evans SR, Yeh T-M, Sacktor N, et al. Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin Trials 2007;8:437-446. (Pubitemid 350305218)
17. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679.
18. Kreis R, Ernst T, Ross BD. Absolute quantitation of water and metabolites in the human brain, II: metabolite concentrations. J Magn Res B 1993;102:9-19.
19. Chang L, Lee PL, Yiannoutsos CT, et al. A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age. Neuroimage 2004;23:1336-1347.
20. Schifitto G, Navia BA, Yiannoutsos CT, et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 2007;21:1877-1886.
21. Ebadi M, Brown-Borg H, Ren J, et al. Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr Drug Targets 2006;7:1513-1529.
22. Turchan-Cholewo J, Liu Y, Gartner S, et al. Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: protection by diosgenin and L-deprenyl. Neurobiol Dis 2006;23:109-119.
23. Czub S, Koutsilieri E, Sopper S, et al. Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. Acta Neuropathol 2001;101:85-91.
24. Czub S, Czub M, Koutsilieri E, et al. Modulation of simian immunodeficiency virus neuropathology by dopaminergic drugs. Acta Neuropathol 2004;107:216-226.
25. Lin A, Ross BD, Harris K, Wong W. Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx 2005;2: 197-214.
26. Chang L, Ernst T, Leonido-Yee M, et al. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology 1999;53:782-789.
27. Chang L, Ernst T, Leonido-Yee M, Walot I, Singer E. Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology 1999;52:100-108.
28. Meyerhoff DJ, Bloomer C, Cardenas V, Norman D, Weiner MW, Fein G. Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients. Neurology 1999;52:995-1003.
29. Salvan AM, Vion-Dury J, Confort-Gouny S, Nicoli F, Lamoureux S, Cozzone PJ. Brain proton magnetic resonance spectroscopy in HIV-related encephalopathy: identification of evolving metabolic patterns in relation to dementia and therapy. AIDS Res Hum Retroviruses 1997; 13:1055-1066.
30. Yiannoutsos CT, Ernst T, Chang L, et al. Regional patterns of brain metabolites in AIDS dementia complex. Neuroimage 2004;23:928-935.
31. Stankoff B, Tourbah A, Suarez S, et al. Clinical and spectroscopic improvement in HIV-associated cognitive impairment. Neurology 2001;56:112-115.
32. Reynolds J, Prost RW, Mark LP. Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease. Brain Res 2005;1031:82-89.
33. Godbolt AK, Waldman AD, MacManus DG, et al. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 2006;66:718-722.
34. Oz G, Terpstra M, Tkac I, et al. Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations. Magn Reson Med 2006;55:296-301.
35. Watanabe H, Fukatsu H, Katsuno M, et al. Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker. J Neurol Neurosurg Psychiatry 2004;75:103-109.
36. Rovaris M, Gambini A, Gallo A, et al. Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. Neurology 2005;65:1626-1630.
37. Benedetti B, Rigotti DJ, Liu S, Filippi M, Grossman RI, Gonen O. Reproducibility of the whole-brain N-acetylaspartate level across institutions, MR scanners, and field strengths. AJNR Am J Neuroradiol 2007;28:72-75.
38. Smith CD, Carney JM, Starke-Reed PE, et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA 1991; 88:10540-10543.
39. Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR. Protein oxidation in the brain in Alzheimer's disease. Neuroscience 2001;103:373-383.
40. Butterfield DA, Reed T, Newman SF, Sultana R. Roles of amyloid [beta]-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 2007;43:658-677.
41. Opii WO, Joshi G, Head E, et al. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease. Neurobiol Aging 2008;29:51-70.
42. Schifitto G, Peterson DR, Zhong J, et al. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology 2006;66:919-921.